Several brokerages have updated their recommendations and price targets on shares of Carlsmed (NASDAQ: CARL) in the last few weeks:
- 11/11/2026 – Carlsmed had its price target raised by Truist Financial from $20.00 to $23.00. They now have a “buy” rating on the stock.
- 11/11/2026 – Carlsmed had its price target raised by BTIG Research from $24.00 to $26.00. They now have a “buy” rating on the stock.
- 11/11/2026 – Carlsmed had its price target raised by Needham & Company LLC from $17.00 to $22.00. They now have a “buy” rating on the stock.
- 11/4/2026 – Carlsmed had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/12/2026 – Carlsmed had its price target raised by BTIG Research from $23.00 to $24.00. They now have a “buy” rating on the stock.
- 9/28/2026 – Carlsmed had its “buy” rating reaffirmed by BTIG Research. They now have a $23.00 price target on the stock.
Carlsmed Stock Performance
CARL traded up $0.72 during trading on Monday, hitting $17.84. 100,726 shares of the stock were exchanged, compared to its average volume of 135,421. The stock has a fifty day moving average price of $14.97 and a two-hundred day moving average price of $12.58. Carlsmed, Inc. has a 1-year low of $8.50 and a 1-year high of $19.15. The firm has a market capitalization of $489.02 million, a P/E ratio of -12.06 and a beta of 1.97. The company has a quick ratio of 5.62, a current ratio of 5.79 and a debt-to-equity ratio of 0.20.
Carlsmed (NASDAQ:CARL – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. The business had revenue of $21.55 million during the quarter. Carlsmed had a negative net margin of 55.82% and a negative return on equity of 42.42%. As a group, sell-side analysts predict that Carlsmed, Inc. will post -1.53 earnings per share for the current year.
Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company’s products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed’s platform is designed to use a patient’s imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.
Read More
- Five stocks we like better than Carlsmed
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
Receive News & Ratings for Carlsmed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carlsmed Inc and related companies with MarketBeat.com's FREE daily email newsletter.
